Ebsteins anomaly of the tricuspid valve ACC/AHA Guidelines for diagnostic tests
Ebsteins anomaly of the tricuspid valve Microchapters | |
Diagnosis | |
---|---|
Treatment | |
Case Studies | |
Ebsteins anomaly of the tricuspid valve ACC/AHA Guidelines for diagnostic tests On the Web | |
American Roentgen Ray Society Images of Ebsteins anomaly of the tricuspid valve ACC/AHA Guidelines for diagnostic tests | |
FDA on Ebsteins anomaly of the tricuspid valve ACC/AHA Guidelines for diagnostic tests | |
CDC on Ebsteins anomaly of the tricuspid valve ACC/AHA Guidelines for diagnostic tests | |
Ebsteins anomaly of the tricuspid valve ACC/AHA Guidelines for diagnostic tests in the news | |
Blogs on Ebsteins anomaly of the tricuspid valve ACC/AHA Guidelines for diagnostic tests | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
ACC / AHA Guidelines- Recommendations for Diagnostic Tests (DO NOT EDIT)
“ |
Class I1. ECG, chest x-ray, and echocardiography-Doppler are recommended for the diagnostic evaluation of Ebstein’s anomaly in adult patients. (Level of Evidence: C) Class IIa1. Pulse oximetry at rest and/or during exercise can be useful in the diagnostic evaluation of Ebstein’s anomaly in adult patients. (Level of Evidence: C) 2. An electrophysiological study can be useful in the diagnostic evaluation of Ebstein’s anomaly in adult patients if a supraventricular arrhythmia is documented or suspected (subsequent radiofrequency catheter ablation should be considered if clinically feasible). (Level of Evidence: C) 3. The following additional diagnostic tests can be useful for the comprehensive evaluation of Ebstein’s anomaly in adult patients: a. Doppler TEE examination if the anatomic information is not provided by transthoracic imaging. (Level of Evidence: B) b. Holter monitoring. (Level of Evidence: B) c. Electrophysiological study for history or ECG evidence of accessory pathway(s). (Level of Evidence: B) d. Coronary angiography, when surgical repair is planned, if there is a suspicion of coronary artery disease, and in men 35 years or older, premenopausal women 35 years or older who have coronary risk factors, and postmenopausal women. (Level of Evidence: B) |
” |